Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. Its products include BTX1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. The company is based in Northbridge, Australia.
Industry, Sector and Symbol
Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolASX:BOT
CUSIPN/A
Phone+61-8-94820580
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-9,889.99%
Return on Equity-188.23%
Return on Assets-168.57%
Miscellaneous
EmployeesN/A
Outstanding Shares543,110,000
Market Cap$60.43
Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions
What is Botanix Pharmaceuticals' stock symbol?
Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."
What is the consensus analysts' recommendation for Botanix Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Botanix Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Botanix Pharmaceuticals' key competitors?
Some companies that are related to Botanix Pharmaceuticals include Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN) and Trillium Therapeutics (TRIL).
Who are Botanix Pharmaceuticals' key executives?
Botanix Pharmaceuticals' management team includes the folowing people:
- Dr. Michael Thurn Ph.D., Chief Operating Officer
- Mr. Matthew Callahan MBA LLB, Exec. Director (Age 45)
- Dr. Henry William Bosch BA, Ph.D., Exec. Director
- Mr. Simon Robertson B.Bus, M Appl. Fin, CA, Company Sec.
Has Botanix Pharmaceuticals been receiving favorable news coverage?
News stories about BOT stock have been trending somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Botanix Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also assigned media stories about the company an impact score of 46.18 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
What is Botanix Pharmaceuticals' stock price today?
One share of BOT stock can currently be purchased for approximately A$0.10.
How big of a company is Botanix Pharmaceuticals?
Botanix Pharmaceuticals has a market capitalization of $60.43 million.
How can I contact Botanix Pharmaceuticals?
Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.
MarketBeat Community Rating for Botanix Pharmaceuticals (ASX BOT)
MarketBeat's community ratings are surveys of what our community members think about Botanix Pharmaceuticals and other stocks. Vote "Outperform" if you believe BOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
